https://orcid.org/0000-0003-2756-6621
Figures & data
Figure 1 Flow diagram of patients included and excluded.
Table 1 Clinical and Laboratory Characteristics of Patients Using Vancomycin Hospitalized in Surgical and Clinical Wards Regarding the Presence or Absence of AKI
Table 2 Characteristics Related to the Use of Vancomycin in Hospitalized Patients in Clinical and Surgical Wards Regarding the Presence or Absence of AKI
Table 3 Cox Regression of Variables Associated with the Presence of AKI in Patients Using Vancomycin Hospitalized in Clinical and Surgical Wards
Figure 2 ROC curve for AKI outcome in septic patients using vancomycin hospitalized in clinical and surgical wards. T0–T2, serum concentration between the start and second day of usage of vancomycin (0–48 hours); T2–T4, serum concentration between the second and fourth days of usage of vancomycin (48–96 hours); T4–T6, serum concentration between the fourth and sixth days of usage of vancomycin (96–144 hours); T6–T8, serum concentration between the sixth and eighth days of usage of vancomycin (144–192 hours).
Figure 3 Free time for acute kidney injury (AKI) according to serum concentration (cutoff 21.5 mg/L) during T4–T6 days (96–144 hours) for use of vancomycin in septic patients in clinical and surgical wards.
Table 4 Clinical and Laboratory Characteristics of Patients Using Vancomycin Hospitalized in Clinical and Surgical Wards According to Outcomes
Table 5 Characteristics Related to the Use of Vancomycin in Hospitalized Patients on Surgical and Clinical Wards Regarding Outcome
Table 6 Cox Regression of Variables Associated with Death in Patients Using Vancomycin Hospitalized in Clinical and Surgical Wards
Figure 4 Free time for death outcome according to serum concentration (cutoff 21.5 mg/L) during T4–T6 for vancomycin in patients hospitalized in surgical and clinical wards. T4–T6, serum concentration between the fourth and sixth days of usage of vancomycin (96–144 hours).
